Q2 2024 Earnings Estimate for Arcadia Biosciences, Inc. Issued By HC Wainwright (NASDAQ:RKDA)

Arcadia Biosciences, Inc. (NASDAQ:RKDAFree Report) – Stock analysts at HC Wainwright raised their Q2 2024 earnings per share estimates for Arcadia Biosciences in a research note issued on Thursday, May 23rd. HC Wainwright analyst R. Selvaraju now anticipates that the basic materials company will post earnings per share of $1.27 for the quarter, up from their previous estimate of ($1.47). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Arcadia Biosciences’ current full-year earnings is ($2.29) per share. HC Wainwright also issued estimates for Arcadia Biosciences’ Q3 2024 earnings at ($1.03) EPS, Q4 2024 earnings at ($0.74) EPS and FY2024 earnings at ($2.29) EPS.

RKDA has been the topic of a number of other research reports. Lake Street Capital upgraded shares of Arcadia Biosciences to a “strong-buy” rating in a research note on Tuesday, May 14th. StockNews.com started coverage on shares of Arcadia Biosciences in a research note on Thursday, May 23rd. They issued a “sell” rating on the stock.

Get Our Latest Research Report on RKDA

Arcadia Biosciences Trading Up 3.2 %

Shares of NASDAQ:RKDA opened at $2.93 on Monday. The business’s 50 day moving average is $2.26 and its 200-day moving average is $2.60. The firm has a market capitalization of $3.98 million, a PE ratio of -0.57 and a beta of 0.62. Arcadia Biosciences has a 1-year low of $1.85 and a 1-year high of $5.60.

Arcadia Biosciences (NASDAQ:RKDAGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The basic materials company reported ($1.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.52) by $0.74. Arcadia Biosciences had a negative net margin of 129.74% and a negative return on equity of 84.27%. The company had revenue of $1.26 million for the quarter, compared to analyst estimates of $1.20 million. During the same period last year, the business posted ($3.83) EPS.

About Arcadia Biosciences

(Get Free Report)

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.

Read More

Earnings History and Estimates for Arcadia Biosciences (NASDAQ:RKDA)

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.